Pharmaceutical patents grant protection to the patentee forth education of the patent term. The patentees enjoy the liberty to determine the prices of medicines, which is time limited to the period of monopoly, but could be unaffordable to the public. Such patent protection offered to the patentees is believed to benefit the public, over 'the longer term through innovations and research and development (R&D), although it comes at a cost, in the nature of higher prices for the patented medicine. The patent regime and price protection - through a legally validated high price for the medicine during the currency of the patent - provide the patentee with a legitimate mechanism to get returns on the costs incurred in innovation and research.
Based on the above passage, the' following assumptions have been made:

Correct Option (C)

Assumptions 3 and 4 are valid based on the provided passage.

• Assumption 3: "Providing medicines to the public at affordable prices is a key goal during the public health policy design in many countries." The passage discusses that patented medicines "could be unaffordable to the public" and highlights the "cost, in the nature of higher prices." This implicitly suggests that affordability is a significant consideration in public health policy, aiming to mitigate the impact of high prices.
• Assumption 4: "Governments need to find an appropriate balance between the rights of patentees and the requirements of the patients." The passage explicitly states, "The patent regime and price protection... provide the patentee with a legitimate mechanism to get returns on the costs incurred in innovation and research," while also noting that prices "could be unaffordable to the public." This directly points to a necessary balance between incentivizing innovation (patentees' rights) and ensuring access to medicines (patients' requirements).

Incorrect Options:

• Assumption 1: "Patent protection given to patentees puts a huge burden on public's purchasing power in accessing patented medicines." While the passage indicates that patented medicines lead to "higher prices" and "could be unaffordable," it does not quantify this impact as a "huge burden on public's purchasing power." The statement exaggerates the degree of burden beyond what is explicitly stated or directly inferable from the text.
• Assumption 2: "Dependence on other countries for pharmaceutical products is a huge burden for developing and poor countries." The passage focuses exclusively on the domestic implications of pharmaceutical patents, pricing, innovation, and affordability. It does not discuss international trade, dependence on foreign countries for pharmaceutical products, or the specific challenges faced by developing and poor countries in this context.